Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Surveillance in this population leads to diagnosis of early-stage disease in one third of patients resulting in increased resectability and a substantial 5-year survival rate
New indication concerns a combination of selinexor with bortezomib and dexamethasone for the treatment of multiple myeloma
Final results of the Unicancer ASTER 70s study
Findings from a pivotal ZUMA-2 study support the investigation of CAR T-cell therapy in earlier lines of treatment
It is approved for use in the older or patients with comorbidities who have acute myeloid leukaemia with a susceptible IDH1 mutation detected by an FDA-approved test
Findings from the MajesTEC-1 study
Findings from the KRYSTAL-1 study
Efficacy was evaluated in the CHECKMATE-648 study
Findings from a prospective phase II study with dostarlimab
Findings from the PEMBROSARC study on presence of tertiary lymphoid structures in patients with advanced soft tissue sarcomas
Findings from a combining analysis of MDS patient samples with CRISPR-DiR technology
Evidence for efficacy is based on the results from the AZA-JMML-001 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
